Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 4:13:33.
doi: 10.1186/1475-2840-13-33.

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Nayyar Iqbal  1 , Artist Parker, Robert Frederich, Mark Donovan, Boaz Hirshberg
Affiliations

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Nayyar Iqbal et al. Cardiovasc Diabetol. .

Abstract

Background: It is important to establish the cardiovascular (CV) safety profile of novel antidiabetic drugs.

Methods: Pooled analyses were performed of 20 randomized controlled studies (N = 9156) of saxagliptin as monotherapy or add-on therapy in patients with type 2 diabetes mellitus (T2DM) as well as a subset of 11 saxagliptin + metformin studies. Adjudicated major adverse CV events (MACE; CV death, myocardial infarction [MI], and stroke) and investigator-reported heart failure were assessed, and incidence rates (IRs; events/100 patient-years) and IR ratios (IRRs; saxagliptin/control) were calculated (Mantel-Haenszel method).

Results: In pooled datasets, the IR point estimates for MACE and individual components of CV death, MI, and stroke favored saxagliptin, but the 95% CI included 1. IRR (95% CI) for MACE in the 20-study pool was 0.74 (0.45, 1.25). The Cox proportional hazard ratio (95% CI) was 0.75 (0.46, 1.21), suggesting no increased risk of MACE in the 20-study pool. In the 11-study saxagliptin + metformin pool, the IRR for MACE was 0.93 (0.44, 1.99). In the 20-study pool, the IRR for heart failure was 0.55 (0.27, 1.12).

Conclusions: Analysis of pooled data from 20 clinical trials in patients with T2DM suggests that saxagliptin is not associated with an increased CV risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incidence rate ratios for saxagliptin vs control (point estimates and 95% CI) for MACE in the 20-study pool, the saxagliptin 2.5- and 5-mg subanalysis, and the add-on to metformin study pool. Numbers in parentheses are total patient-years of exposure (the time up to an event or censoring). IRR = incidence rate ratio; MACE = major adverse cardiovascular events; MET = metformin; SAXA = saxagliptin.
Figure 2
Figure 2
Incidence rate ratios for saxagliptin vs control (point estimates and 95% CI) for CV death, myocardial infarction, stroke, and heart failure in the 20-study pool. Numbers in parentheses are total patient-years of exposure (the time up to an event or censoring). CV = cardiovascular; IRR = incidence rate ratio; MACE = major adverse cardiovascular events; SAXA = saxagliptin.
Figure 3
Figure 3
Incidence rate ratios for saxagliptin vs control (point estimates and 95% CI) for CV death, myocardial infarction, and stroke in the add-on to metformin study pool. Numbers in parentheses are total patient-years of exposure (the time up to an event or censoring). CV = cardiovascular; IRR = incidence rate ratio; SAXA = saxagliptin.
See this image and copyright information in PMC

References

    1. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. [ http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf]
    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS. et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. doi: 10.1161/CIR.0b013e31828124ad. - DOI - PMC - PubMed
    1. Cavalot F, Pagliarino A, Valle M, Di Martino L, Bonomo K, Massucco P, Anfossi G, Trovati M. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34(10):2237–2243. doi: 10.2337/dc10-2414. - DOI - PMC - PubMed
    1. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26(3):688–696. doi: 10.2337/diacare.26.3.688. - DOI - PubMed
    1. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431. doi: 10.7326/0003-4819-141-6-200409210-00007. - DOI - PubMed

Publication types

MeSH terms